Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014

  • Email
  • Help

News

21/11/2014

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014

Ten new medicines, two orphans, recommended for approval

Ten new medicines have been recommended for approval at the November 2014 meeting of the Committee for Medicinal Products for Human Use (CHMP).

The CHMP has recommended granting a marketing authorisation for Cerdelga (eliglustat), an orphan medicine for the treatment of Gaucher disease type 1. For more information please see the press release in the grid below.

The Committee also gave positive opinions for Exviera (dasabuvir) and Viekirax (ombitasvir + paritaprevir + ritonavir) for the treatment of chronic hepatitis C. Both products were reviewed under accelerated assessment and belong to a new generation of antiviral products for chronic hepatitis C infection that have high cure rates and have recently reshaped the treatment landscape for the disease. For more information please see the press release in the grid below.

The orphan medicine Ofev (nintedanib) received a positive opinion for the treatment of idiopathic pulmonary fibrosis.

Cosentyx (secukinumab) and Otezla (apremilast) were recommended by the CHMP as new treatment options for psoriasis.

Senshio (ospemifene) received a positive opinion for the treatment of vulvar and vaginal atrophy and Zontivity (vorapaxar) was recommended for the reduction of atherothrombotic events.

The CHMP also granted positive opinions for two new informed consent applications: Sevelamer carbonate Zentiva (sevelamer) for the control of hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis and Rasagiline ratiopharm (rasagiline) for the treatment of Parkinson’s disease. An informed consent application is based on data from the dossier of a previously authorised medicine, with the marketing authorisation holder of that medicine giving consent for the use of their data in the application.

Two recommendations on extensions of therapeutic indications

The Committee recommended extensions of indications for Inductos and Travatan.

Change to non-prescription status

The CHMP recommended a change in classification status from prescription to non-prescription for the emergency contraceptive ellaOne (ulipristal acetate). For more information, please see the press release in the grid below.

Outcome of safety review

The CHMP concluded its review of Corlentor/Procoralan (ivabradine) and made recommendations aimed at reducing the risk of heart problems, including heart attack and bradycardia (excessively low heart rate), in patients taking the medicine for angina. Corlentor/Procoralan is used to treat symptoms of angina (chest pain due to problems with the blood flow to the heart) and to treat heart failure.

Update on Tecfidera

The CHMP discussed a fatal case of progressive multifocal leukoencephalopathy (PML) which was reported in a patient treated with Tecfidera (dimethyl fumarate), a medicine used for relapsing-remitting multiple sclerosis. This is the first case of PML, a rare viral brain infection with symptoms that can be similar to those of a multiple sclerosis attack, to be reported in association with Tecfidera. The fatal case of PML occurred after long-term treatment with the medicine in a patient experiencing severe long-term lymphopenia, a known possible side effect of Tecfidera.

The CHMP recommended that a letter is sent to healthcare professionals to alert them to the potential risk of PML and to allow them to inform their patients.

Withdrawals of applications

The application for a marketing authorisation for Egranli has been withdrawn. For more information, please see the question-and-answer document in the grid below.

An application for an extension of therapeutic indication for Ceprotin has been withdrawn. A question-and-answer document on the withdrawal is available below.

More information on other outcomes of the November 2014 CHMP meeting, is available in the grid below.

Agenda and minutes

The agenda of the November 2014 meeting is published on the EMA website. The minutes of the October meeting will be published during the week following the November CHMP meeting.

CHMP statistics

Key figures from the November 2014 CHMP meeting are represented in the graphic below.

 

Positive recommendations on new medicines

Name of medicineCerdelga
International non-proprietary name (INN)eliglustat
Marketing-authorisation applicantGenzyme Europe BV
Therapeutic indicationTreatment of Gaucher disease type 1
More information

Summary of opinion for Cerdelga

 

Press release: Cerdelga recommended for approval in type 1 Gaucher disease

 

Name of medicineCosentyx
INNsecukinumab
Marketing-authorisation applicantNovartis Europharm Ltd
Therapeutic indicationTreatment of psoriasis
More informationSummary of opinion for Cosentyx

 

Name of medicineExviera
INNdasabuvir
Marketing-authorisation applicantAbbVie Ltd
Therapeutic indicationTreatment of chronic hepatitis C
More information

Summary of opinion for Exviera

 

Press release: Two new medicines recommended for the treatment of chronic hepatitis C

 

Name of medicineOfev
INNnintedanib
Marketing-authorisation applicantBoehringer Ingelheim International GmbH
Therapeutic indicationTreatment of idiopathic pulmonary fibrosis
More informationSummary of opinion for Ofev

 

Name of medicineOtezla
INNapremilast
Marketing-authorisation applicantCelgene Europe Limited
Therapeutic indicationTreatment of psoriasis
More informationSummary of opinion for Otezla

 

Name of medicineSenshio
INNospemifene
Marketing-authorisation applicantShionogi Limited
Therapeutic indicationTreatment of vulvar and vaginal atrophy
More informationSummary of opinion for Senshio

  

Name of medicineViekirax
INNombitasvir / paritaprevir / ritonavir
Marketing-authorisation applicantAbbVie Ltd
Therapeutic indicationTreatment of chronic hepatitis C
More information

Summary of opinion for Viekirax

 

Press release: Two new medicines recommended for the treatment of chronic hepatitis C

 

Name of medicineZontivity
INNvorapaxar
Marketing-authorisation applicantMerck Sharp & Dohme Limited
Therapeutic indicationReduction of atherothrombotic events
More informationSummary of opinion for Zontivity

 

Positive recommendations on informed-consent applications

Name of medicineRasagiline ratiopharm
INNrasagiline
Marketing-authorisation applicantTeva B.V.
Therapeutic indicationTreatment of Parkinson's disease
More informationSummary of opinion for Rasagiline ratiopharm

 

Name of medicineSevelamer carbonate Zentiva
INNsevelamer
Marketing-authorisation applicantGenzyme Europe BV
Therapeutic indicationControl of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis
More informationSummary of opinion for Sevelamer carbonate Zentiva

 

Positive recommendations on extensions of therapeutic indications

Name of medicineInductos
INNdibotermin alfa
Marketing-authorisation holderMedtronic BioPharma B.V.
More informationSummary of opinion for Inductos

 

Name of medicineTravatan
INNtravoprost
Marketing-authorisation holderAlcon Laboratories (UK) Ltd
More informationSummary of opinion for Travatan

 

Public-health recommendation

Name of medicineCorlentor / Procoralan
INNivabradine hydrochloride
Marketing-authorisation holderLes Laboratoires Servier
More informationCorlentor and Procoralan

 

Outcome of arbitration procedure

Name of medicineNasonex
INNmometasone
Marketing-authorisation holderMerck Sharp & Dohme
More informationNasonex

 

Withdrawals of applications

Name of medicineCeprotin
INNhuman protein C
More informationCeprotin

 

Name of medicineEgranli
INNbalugrastim
More informationEgranli

 

Other outcome

Name of medicineellaOne
INNulipristal acetate
Marketing-authorisation holderLaboratoire HRA Pharma SA
More information

Summary of opinion for ellaOne

 

Press release: EMA recommends availability of ellaOne emergency contraceptive without prescription

 

Other updates

Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures
Opinions on safety variations
Start of Community reviews
Scientific advice and protocol assistance
Guidelines and concept papers adopted
Organisational matters
Opinions on consultation procedures on ancillary medicinal substances in medical devices

 

How useful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Related content

Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore, users are asked to check the page regularly.

Contact point:

Monika Benstetter
Tel. +44 (0)20 3660 8427
E-mail: press@ema.europa.eu